JP2018511627A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511627A5
JP2018511627A5 JP2017553877A JP2017553877A JP2018511627A5 JP 2018511627 A5 JP2018511627 A5 JP 2018511627A5 JP 2017553877 A JP2017553877 A JP 2017553877A JP 2017553877 A JP2017553877 A JP 2017553877A JP 2018511627 A5 JP2018511627 A5 JP 2018511627A5
Authority
JP
Japan
Prior art keywords
methyl
pyrido
oxo
trifluoromethyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017553877A
Other languages
English (en)
Japanese (ja)
Other versions
JP6847851B2 (ja
JP2018511627A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/057962 external-priority patent/WO2016166078A1/en
Publication of JP2018511627A publication Critical patent/JP2018511627A/ja
Publication of JP2018511627A5 publication Critical patent/JP2018511627A5/ja
Application granted granted Critical
Publication of JP6847851B2 publication Critical patent/JP6847851B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017553877A 2015-04-15 2016-04-12 Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用 Active JP6847851B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015076617 2015-04-15
CNPCT/CN2015/076617 2015-04-15
PCT/EP2016/057962 WO2016166078A1 (en) 2015-04-15 2016-04-12 Pyridopyrimidinones and their use as nmda receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020200946A Division JP2021046428A (ja) 2015-04-15 2020-12-03 Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用

Publications (3)

Publication Number Publication Date
JP2018511627A JP2018511627A (ja) 2018-04-26
JP2018511627A5 true JP2018511627A5 (cg-RX-API-DMAC7.html) 2019-05-16
JP6847851B2 JP6847851B2 (ja) 2021-03-24

Family

ID=55809078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017553877A Active JP6847851B2 (ja) 2015-04-15 2016-04-12 Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用
JP2020200946A Pending JP2021046428A (ja) 2015-04-15 2020-12-03 Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020200946A Pending JP2021046428A (ja) 2015-04-15 2020-12-03 Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用

Country Status (19)

Country Link
US (1) US10280165B2 (cg-RX-API-DMAC7.html)
EP (1) EP3283487B1 (cg-RX-API-DMAC7.html)
JP (2) JP6847851B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170137137A (cg-RX-API-DMAC7.html)
CN (1) CN107531696B (cg-RX-API-DMAC7.html)
AU (1) AU2016248886B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017021083A2 (cg-RX-API-DMAC7.html)
CA (1) CA2982217A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002498A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017009989A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170462A (cg-RX-API-DMAC7.html)
IL (1) IL254921B (cg-RX-API-DMAC7.html)
MX (1) MX373162B (cg-RX-API-DMAC7.html)
PE (1) PE20180316A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501876A1 (cg-RX-API-DMAC7.html)
RU (1) RU2717665C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201708294YA (cg-RX-API-DMAC7.html)
UA (1) UA120647C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016166078A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016004540A (es) 2013-10-11 2016-07-21 Hoffmann La Roche Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
JP6847851B2 (ja) 2015-04-15 2021-03-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用
HUE051395T2 (hu) 2015-12-09 2021-03-01 Cadent Therapeutics Inc Heteroaromás NMDA receptor modulátorok és alkalmazásaik
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
ES2951872T3 (es) 2018-08-03 2023-10-25 Novartis Ag Moduladores del receptor NMDA heteroaromáticos y usos de los mismos
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
AU2021267161A1 (en) 2020-05-04 2022-12-08 Amgen Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
DE602004025698D1 (de) * 2003-06-20 2010-04-08 Novartis Vaccines & Diagnostic PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP2079737A1 (en) * 2007-02-05 2009-07-22 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
KR101811549B1 (ko) * 2013-06-19 2017-12-26 에프. 호프만-라 로슈 아게 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체
MX2016004540A (es) 2013-10-11 2016-07-21 Hoffmann La Roche Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
JP6847851B2 (ja) 2015-04-15 2021-03-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用

Similar Documents

Publication Publication Date Title
JP2018511627A5 (cg-RX-API-DMAC7.html)
JP2019505541A5 (cg-RX-API-DMAC7.html)
JP2013515729A5 (cg-RX-API-DMAC7.html)
FI3932919T3 (fi) Jak-inhibiittoriyhdiste ja sen käyttö
JP2013500247A5 (cg-RX-API-DMAC7.html)
HRP20231614T1 (hr) Spojevi pirolotriazina kao tam inhibitori
CN112074505B (zh) 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物
JP2014513110A5 (cg-RX-API-DMAC7.html)
JP2014505735A5 (cg-RX-API-DMAC7.html)
JP2014505696A5 (cg-RX-API-DMAC7.html)
ES2543904T9 (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
JP2013505930A5 (cg-RX-API-DMAC7.html)
RU2017139254A (ru) Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата
JP2020526549A5 (cg-RX-API-DMAC7.html)
FI3773593T3 (fi) Hidradenitis suppurativan hoito jak-estäjiä käyttäen
JP2013523889A5 (cg-RX-API-DMAC7.html)
JP2011252024A5 (cg-RX-API-DMAC7.html)
JP2009532452A5 (cg-RX-API-DMAC7.html)
JP2014511893A5 (cg-RX-API-DMAC7.html)
JP2014513139A5 (cg-RX-API-DMAC7.html)
JP6814730B2 (ja) 治療用化合物およびその使用
JP2019525939A5 (cg-RX-API-DMAC7.html)
JP2020536915A5 (cg-RX-API-DMAC7.html)
JP2010510202A5 (cg-RX-API-DMAC7.html)
JP2016520118A5 (cg-RX-API-DMAC7.html)